The Drugs.com Monthly Update Podcast

Drugs.com
  • 0.0 (0)
  • MEDICINE

The "Monthly Update" Podcast from Drugs.com delivers monthly roundups of new drug approvals, updated indications, safety alerts, and the latest healthcare news.

Episodes

  1. Drugs.com - Monthly Update January 2026

    FEB 2

    Drugs.com - Monthly Update January 2026

    In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin. Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.Zycubo (copper histidinate), the first treatment for Menkes disease in children.Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.Chapters (00:00) - Intro (00:21) - Overview (00:47) - Darzalex (02:13) - Yuvezzi (03:06) - Zycubo (03:50) - Nexplanon (04:35) - Afrezza (05:09) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    6 min
  2. Drugs.com - Monthly Update December 2025

    JAN 1

    Drugs.com - Monthly Update December 2025

    This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.Chapters (00:00) - Intro (00:22) - Overview (00:34) - Wegovy (01:16) - Myqorzo (02:07) - Exdensur (02:56) - Jaypirca (03:31) - Lerochol (04:09) - Breyanzi (04:46) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    5 min
  3. Drugs.com - Monthly Update November 2025

    12/01/2025

    Drugs.com - Monthly Update November 2025

    In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike. Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for adults with relapsed or refractory follicular lymphoma, showing a 79% reduction in disease progression risk through T-cell engagement with malignant B-cells.Darzalex Faspro (daratumumab and hyaluronidase-fihj), now the first and only approved treatment for patients with high-risk smoldering multiple myeloma, significantly slowing disease progression.Eylea HD (aflibercept ophthalmic), approved for macular edema following retinal vein occlusion with extended up to every 8-week dosing after initial treatment, maintaining visual acuity with less frequent administration.Caplyta (lumateperone), newly approved as an add-on therapy for adults with major depressive disorder, enhancing outcomes when used alongside existing antidepressants.Chapters: (00:00) - Intro (00:37) - Discussion points (00:47) - Keytruda (01:20) - Epkinly (02:10) - Darzalex (02:47) - Eylea HD (03:14) - Caplyta (03:43) - Key takeaways (04:02) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    4 min
  4. Drugs.com - Monthly Update October 2025

    11/01/2025

    Drugs.com - Monthly Update October 2025

    This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes. Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes.Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children.Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment.Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause.Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema.Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis.Chapters: (00:00) - Intro (00:40) - Rybelsus (01:36) - Zoryve Cream (02:17) - Gazyva (02:51) - Lynkuet (03:01) - Lasix ONYU (03:44) - Jascayd (04:16) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    5 min
  5. Drugs.com - Monthly Update September 2025

    10/01/2025

    Drugs.com - Monthly Update September 2025

    Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike. Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing symptoms despite antihistamine therapy.Palsonify (paltusotine) introduces a groundbreaking once-daily oral option for acromegaly, offering rapid control of growth hormone levels.Inluriyo (imlunestrant), a significant development for treating ESR1-mutated breast cancer in patients who have experienced disease progression after endocrine therapy.Forzinity (elamipretide hydrochloride) provides hope for children with Barth syndrome by improving muscle strength through mitochondrial support.Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a quicker subcutaneous option for pembrolizumab administration, simplifying immunotherapy for melanoma and non-small cell lung cancer patients.Chapters (00:25) - Intro (00:51) - Rhapsido (01:47) - Palsonify (02:48) - Inluriyo (03:33) - Forzinity (04:09) - Keytruda Qlex (04:45) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    5 min
  6. Drugs.com - Monthly Update August 2025

    09/01/2025

    Drugs.com - Monthly Update August 2025

    August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice. Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new treatment pathway for this progressive liver condition.Tonmya (cyclobenzaprine) for fibromyalgia: A potent sublingual treatment, provides hope in managing fibromyalgia's chronic pain and sleep disturbances.Ajovy (fremanezumab) for pediatric migraines: The first anti-CGRP therapy approved for migraine prevention in children, opening new avenues for managing this debilitating condition.Repatha (evolocumab) for cardiovascular risk: Expanded use in adults at risk for major cardiovascular events, even absent diagnosed cardiovascular disease.Brinsupri (brensocatib) for bronchiectasis: Provides a novel oral option for reducing flares in non-cystic fibrosis bronchiectasis, promising symptom relief.Chapters: (00:00) - Intro (00:41) - Wegovy (01:41) - Tonmya (02:32) - Ajovy (03:19) - Repatha (03:57) - Brinsupri (04:26) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    5 min
  7. Drugs.com - Monthly Update July 2025

    08/02/2025

    Drugs.com - Monthly Update July 2025

    This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements. Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo.Anzupgo (delgocitinib), the first steroid-free topical treatment approved in the U.S. for moderate to severe chronic hand eczema in adults, working as a pan-Janus kinase inhibitor with twice-daily application to affected areas.Kisunla (donanemab-azbt), now available with an updated once-monthly dosing regimen for early symptomatic Alzheimer's disease, showing a 41% reduction in ARIA-E (amyloid-related imaging abnormalities with edema) at 24 weeks while targeting and removing beta-amyloid plaques in the brain.Chapters (00:00) - Intro (00:24) - Overview (00:47) - Angioedema (01:10) - Ekterly (01:51) - Anzupgo (02:54) - Kisunla (03:45) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    4 min
  8. Drugs.com - Monthly Update June 2025

    07/02/2025

    Drugs.com - Monthly Update June 2025

    This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas. Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.Enflonsia (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.Ibtrozi (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.Chapters: (00:00) - Intro (00:24) - Overview (00:45) - Dupixent (01:38) - Mavyret (02:14) - Yeztugo (03:14) - Enflonsia (03:54) - Ibtrozi (04:26) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    5 min
  • 8 Episodes

About

The "Monthly Update" Podcast from Drugs.com delivers monthly roundups of new drug approvals, updated indications, safety alerts, and the latest healthcare news.

Information